[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360554-105":59,"doc-detail-360554-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","preclinical-efficacy-of-combinatorial-b7-h3-car-t-cells-and-onc206-against-diffuse-intrinsic-pontine-glioma","Preclinical efficacy of combinatorial B7-H3 CAR T cells and ONC206 against diffuse intrinsic pontine glioma","","Diffuse intrinsic pontine glioma (DIPG) is a fatal pediatric brain tumor with limited treatment options and dismal outcomes. The study evaluates whether combining B7-H3-targeting chimeric antigen receptor (CAR) T cells with ONC206 can overcome heterogeneous clinical results seen with single-agent strategies. Experiments test the combination across DIPG cell cultures and orthotopic xenograft mouse models to assess cytotoxicity, immune signaling, mitochondrial dysfunction, and survival effects.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/preclinical-efficacy-of-combinatorial-b7-h3-car-t-cells-and-onc206-against-diffuse-intrinsic-pontine-glioma/360554/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/preclinical-efficacy-of-combinatorial-b7-h3-car-t-cells-and-onc206-against-diffuse-intrinsic-pontine-glioma/360554.png","ImageObject",300,407,{"name":92,"@type":93},"Mimi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why combine B7-H3 CAR T cells with ONC206 for DIPG?","Question",{"text":113,"@type":114},"Single-agent CAR T strategies for DIPG may not provide uniform clinical benefit. The study combines B7-H3 CAR T cells with ONC206 to pursue enhanced, multi-agent anti-tumor activity.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What does ONC206 do in relation to DIPG cells and CAR T activity?",{"text":118,"@type":114},"ONC206 induces significant mitochondrial dysfunction in DIPG cells. It does not substantially impair CAR T metabolic fitness and effector function, supporting integration with cellular therapy.",{"name":120,"@type":111,"acceptedAnswer":121},"What results were observed in vitro and in vivo?",{"text":122,"@type":114},"In vitro, combining low effector-to-target ratios of B7-H3 CAR T cells with ONC206 increases cytotoxicity and elevates IL-2, IL-29, VEGF-A, and Granzyme B. In vivo, the combination extends survival in orthotopic DIPG xenograft mouse models.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},360554,1790295052,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},2336477974920,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Neuro-Oncology 1301  \n28(5), 1301–1315, 2026 | [https://doi.org/10.1093/neuonc/noag025 | Advance Access](https://doi.org/10.1093/neuonc/noag025 | Advance Access) publication 04 February 2026  \nPreclinical efficacy of combinatorial B7-H3 CAR T cells and ONC206 against diffuse intrinsic pontine glioma  \nAndrea Timpanaro, Edward Z. Song, RymaToumi, Leonel Elena-Sanchez, Caroline Piccand, Kelsey M. Nemec, Anja Kordowski, Davina Lau, Scott Johnson, Lily Winter, Ashmitha Rajendran, Rebecca Ronsley, Shannon K. Oda, Joshua A. Gustafson, Jason P. Wendler, Carl Koschmann, Myron Evans, Siobhan Pattwell, Michael C. Jensen, Jessica B. Foster, Matthew D. Dun, Michael Meechan, Matthew C. Biery, and Nicholas A. Vitanza   \nAll author affiliations are listed at the end of the article  \nCorresponding Author: Nicholas A. Vitanza, MD, BenTowne Center for Childhood Cancer and Blood Disorders Research, Seattle Children’s Research Institute, Seattle, WA 98101, USA; Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA, USA; Seattle Children’sTherapeutics, Seattle, WA, USA ([nicholas.vitanza@seattlechildrens.org](nicholas.vitanza@seattlechildrens.org)).  \nAbstract  \nBackground. Diffuse intrinsic pontine glioma (DIPG) is a fatal pediatric brain tumor affecting over 300 children annually in the United States. Chimeric antigen receptor (CAR) T cells are a targeted immune effector cell therapy with substantial clinical benefit against hematologic cancers. Against central nervous system (CNS) tumors, CART cells targeting B7-H3, a protein highly expressed on DIPG, have rapidly advanced from preclinical studies to clinical trials. BrainChild-03 (NCT04185038), a phase 1 trial of repeatedly delivered intracerebroventricular (ICV) B7-H3-targeting CART cells (B7-H3 CART cells), demonstrated tolerability and potential efficacy for children and young adults with DIPG. However, clinical benefits were not uniformly seen, and multi-agent treatment strategies may be required against such an aggressive disease. Here, we combined B7-H3 CAR T cells with ONC206, an imipridone molecule also under clinical investigation.  \nMethods. We tested B7-H3 CAR T cells combined with ONC206 across multiple DIPG cell cultures and orthotopic xenograft mouse models.  \nResults. B7-H3 CART cell monotherapy induced robust cytotoxicity while ONC206 treatment resulted in significant mitochondrial dysfunction against DIPG cells. The combination of low effector-to-target ratios of B7-H3 CART cells and IC50 concentrations of ONC206 led to significantly enhanced cytotoxicity in vitro ( P\u003C .003) and increased IL-2, IL-29, VEGF-A, and Granzyme B levels. In vivo combinatorial studies of ONC206 and a single ICV dose of B7-H3 CAR T cells extended survival in DIPG xenograft mouse models.  \nConclusions. B7-H3 CAR T cells combined with ONC206 are a feasible and efficacious multi-agent approach against multiple DIPG models.  \nKey Points  \n• B7-H3 CAR T cells and ONC206 target vulnerabilities in DIPG.  \n• ONC206 does not substantially impair CAR T cell metabolic fitness and effector function, supporting its integration with cellular therapy.  \n• B7-H3 CAR T cells and ONC206 have combinatorial efficacy against DIPG.  \nReceived August 7, 2025; accepted January 29, 2026.  \n© The Author(s) 2026. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License ( [https://creativecom](https://creativecom)[mons.org/licenses/by-nc/4.0/](mons.org/licenses/by-nc/4.0/)), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [reprints@oup.com](reprints@oup.com) for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—f","cbCaibmaK4q4ApJb","https://ap.wps.com/l/cbCaibmaK4q4ApJb","pdf",5785125,15,"English","# Background\n## Rationale for combination therapy\n# Methods\n## DIPG cell cultures and orthotopic xenograft models\n# Results\n## Cytotoxicity and mitochondrial dysfunction\n## In vitro immune signaling and IL-2/VEGF changes\n## In vivo survival extension\n# Conclusions","[{\"question\":\"Why combine B7-H3 CAR T cells with ONC206 for DIPG?\",\"answer\":\"Single-agent CAR T strategies for DIPG may not provide uniform clinical benefit. The study combines B7-H3 CAR T cells with ONC206 to pursue enhanced, multi-agent anti-tumor activity.\"},{\"question\":\"What does ONC206 do in relation to DIPG cells and CAR T activity?\",\"answer\":\"ONC206 induces significant mitochondrial dysfunction in DIPG cells. It does not substantially impair CAR T metabolic fitness and effector function, supporting integration with cellular therapy.\"},{\"question\":\"What results were observed in vitro and in vivo?\",\"answer\":\"In vitro, combining low effector-to-target ratios of B7-H3 CAR T cells with ONC206 increases cytotoxicity and elevates IL-2, IL-29, VEGF-A, and Granzyme B. In vivo, the combination extends survival in orthotopic DIPG xenograft mouse models.\"}]","Preclinical efficacy of combinatorial B7-H3 CAR T cells and ONC206 against diffuse intrinsic pontine glioma | PDF",1790140497,38,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b32a011060067cc62fc72173cd4152d5.webp",983,1296,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/edf2edc3d5e41d60d2001056a26cf15f.webp",982,1294,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4052a7cddbc46e83706f89e7c9123459.webp",981,1293,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ac1e242872a35b5ac568513a062c230e.webp",980,1292]